Prior allergic reaction to carboplatin, paclitaxel, and/or cisplatin
Prior treatment with protein-bound paclitaxel allowed if it has been six months since received or progressed on protein-bound paclitaxel and plan to continue to receive protein-bound paclitaxel with MinnelideTMcapsules
paclitaxel
Prior treatment with paclitaxel as part of definitive therapy regimen is acceptable, provided the patient is not intolerant of paclitaxel.
Patients who are not eligible to receive paclitaxel will be allowed to receive single agent DKN-.
History of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor EL (polyoxyethylated castor oil). Patients who exhibit these hypersensitivities will be eligible to receive single agent DKN-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone or paclitaxel/nab-paclitaxel; patients with a history of mild infusion reactions with paclitaxel who were able to continue to receive paclitaxel with corticosteroid premedication will be eligible to participate, as these cases were likely related to cremaphor and not paclitaxel
Platinum-resistant or -sensitive after completing first-line treatment (debulking surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as carboplatin and paclitaxel). Subjects may have had any number of subsequent lines of chemotherapy.
Carboplatin or paclitaxel exposure within past  months.
History of allergic reactions to carboplatin or paclitaxel
Known hypersensitivity to pirfenidone, carboplatin, pemetrexed or paclitaxel
Conditions that would prohibit intermittent administration of corticosteroids for paclitaxel premedication; however, corticosteroid can be dropped after confirming of no asthma like reaction to paclitaxel after  doses
Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist; no other investigational or commercial therapeutic agents may be given concurrently with the paclitaxel
The planned treatment regimen must be concurrent chemoradiation with carboplatin-paclitaxel followed by surgery
History of anaphylaxis or serious allergic reaction to carboplatin or paclitaxel
Patients receiving any other investigational agents or are unable to be treated with doxorubicin, cyclophosphamide, and paclitaxel
Patients with a histologically confirmed or presumed diagnosis of gynecologic malignancy for whom chemotherapy with paclitaxel and carboplatin is planned
Consultation with a medical oncologist at enrolling site =<  days prior to registration, with determination that treatment with neoadjuvant chemoradiotherapy with weekly carboplatin and paclitaxel is considered acceptable
Planned chemotherapy with combination carboplatin and paclitaxel given intravenously
History of hypersensitivity to paclitaxel or carboplatin or their excipients
Patients with known history of hypersensitivity to paclitaxel that did not resolve with pre-medication
Prior treatment with paclitaxel in the metastatic setting is not allowed (patients who received neoadjuvant paclitaxel can be included)
Patients with a history of prior therapy with paclitaxel and/or carboplatin
Must be a candidate for treatment with either carboplatin plus paclitaxel or carboplatin plus PLD
Patients must be, after evaluation by the investigator, appropriate candidates for the administration of  to  cycles of standard platinum-based combination chemotherapy (carboplatin and paclitaxel, carboplatin and liposomal doxorubicin, or carboplatin and gemcitabine) following CRS with or without HIPEC
Subjects with any tumor type (except lung) for which carboplatin plus paclitaxel chemotherapy would be appropriate  Paclitaxel Arm:
Subjects with any tumor type (except lung) for which paclitaxel chemotherapy would be appropriate  Anastrozole Arm:
Carboplatin Plus Paclitaxel Arm:
Subjects who were previously treated with carboplatin and paclitaxel for locally advanced and/or metastatic disease and who received the last dose of the drug(s) ?  months prior to the first dose of the study treatment may be enrolled
Subjects who were not previously treated with carboplatin and paclitaxel for locally advanced and/or metastatic disease and for whom, in the opinion of the Investigator, this chemotherapy regimen is appropriate may be enrolled
Paclitaxel Arm:
Subjects who were previously treated with paclitaxel for locally advanced and/or metastatic disease and who in the opinion of the Investigator may benefit from the combination treatment of ARQ  and paclitaxel may be enrolled
For subjects enrolled in the Carboplatin Plus Paclitaxel Arm or Paclitaxel Arm, concurrent standard long-term anticancer hormonal therapy with drugs including but not limited to selective estrogen receptor modulators or Gonadotropin-releasing hormone (GnRH) analogs if started at least six months before the first dose of study treatment is allowed
Carboplatin and/or paclitaxel defined by the Investigator based on the Food and Drug Administration (FDA) approved labeling or institutional standard of care (SOC)
History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin hydrochloride (HCL) or the components of doxil, paclitaxel, or carboplatin
Patient is suitable to receive standard chemotherapy with radiation during weeks - (e.g. cisplatin+ etoposide or carboplatin+paclitaxel)
History of hypersensitivity to paclitaxel
ELIGIBILITY CRITERIA FOR REGISTRATION: the subject and her physician must agree to  cycles (a total of up to  cycles will be allowed) of one of the standard of care regimens allowed on this protocol; these regimens (starting dosage) include:\r\n* <  years of age:\r\n** R: IV paclitaxel  mg/m^ and carboplatin area under the curve (AUC) - every  days\r\n** R: IV docetaxel  mg/m^ and carboplatin AUC - every  days\r\n** R: IV paclitaxel  mg/m^ day , , and  and carboplatin AUC - day  every  days\r\n* >=  years of age may (but not required to) choose one of the following alternative regimens:\r\n** R: IV paclitaxel  mg/m^ plus IV carboplatin AUC  plus optional filgrastim (G-CSF) every  days\r\n** R: IV paclitaxel  mg/m^ day , , and  plus IV carboplatin AUC  day  every  days (day  paclitaxel optional)\r\n** R: IV paclitaxel  mg/m^ plus IV carboplatin AUC  day , , and  every  days\r\n*** Use of granulocyte colony stimulating factor is permitted, but additional chemotherapy agents (e.g. gemcitabine) or biologic agents (e.g. bevacizumab) are not; dose modifications for patients >= age  are allowable as indicated above; patients >= age  for whom the physician deems carboplatin AUC  to be unsafe may be treated with AUC 
Previous inability to tolerate any dose of paclitaxel (i.e., the subject required a paclitaxel dose reduction or discontinuation).
Subjects who have history of severe hypersensitive reaction to the active ingredient or any excipients of DHP or IV paclitaxel.
Known allergic reaction to talimogene laherparepvec, paclitaxel, aromatase inhibitors, tamoxifen, fulvestrant, or any of their components; an exception is made if the patient will not be receiving the offending agent/component (i.e. a patient who is allergic to paclitaxel but will be receiving endocrine therapy is eligible)
Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
Participants may have received prior treatment with weekly paclitaxel; however, participants who have had progression on or within  weeks of their last dose of weekly paclitaxel will not be eligible
Patients with any history of allergic reaction to paclitaxel or other taxanes or carboplatin
Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow  or E), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow  or E) or known contraindications to any study supplied drug.
Patients with recurrent disease may have received prior treatment with carboplatin/paclitaxel but must have had a treatment free interval of >  months
Participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (Cremophor).
Known history of allergic reaction to cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow  or E), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow  or E) or known contraindications to any study supplied drug.
Any contraindication to the use of cisplatin, carboplatin, or paclitaxel chemotherapy
Weekly paclitaxel for recurrent or persistent disease.
Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin;
Has known hypersensitivity to paclitaxel
Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy
Must have completed concurrent chemoradiation with a standard chemotherapy regimen (either cisplatin/etoposide or carboplatin/paclitaxel) and a dose of radiation ranging from .-.Gy
Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).
History of prior paclitaxel therapy
Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
Deemed eligible to receive neoadjuvant chemotherapy with  cycles of weekly taxane therapy (paclitaxel  mg/m or abraxane  mg/m if there is a shortage of paclitaxel) followed by  cycles of adriamycin ( mg/m) and cyclophosphamide ( mg/m) given every  weeks with growth-factor support
Known hypersensitivity to doxorubicin, cyclophosphamide, paclitaxel, Cremophor or medications containing Cremophor (miconazole, docetaxel, Sandimmune, nelfinavir mesylate, propofol, diazepam injection, vitamin K injection, ixabepilone, Aci-Jel) or carboplatin
Known hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.
Known hypersensitivity to protein bound paclitaxel
No known prior hypersensitivity to carboplatin, paclitaxel, bevacizumab or hydroxychloroquine or any of their components
History of known allergy or contraindications to the use of pazopanib, paclitaxel, or carboplatin
CARBOPLATIN AND PACLITAXEL ARMS: absolute neutrophil count >= ,/mL
CARBOPLATIN AND PACLITAXEL ARMS: platelets >= ,/mL
PACLITAXEL ARM: hypersensitivity to paclitaxel or any component of the formulation
Weekly paclitaxel must be an acceptable treatment option
Patients who have experienced a previous grade  or  anaphylactic reaction to paclitaxel
Cytotoxic chemotherapy, such as dacarbazine, temozolomide, carboplatin +/-paclitaxel.
Patients with prior therapy with paclitaxel or other taxanes.
Prior treatment with paclitaxel and carboplatin for recurrent platinum-sensitive ovarian cancer
Prior treatment with PM or weekly paclitaxel or nanoalbumin-paclitaxel
Patients who have previously discontinued paclitaxel-based regimes due to drug related toxicity.
have not been treated with weekly paclitaxel after first-line treatment in which weekly paclitaxel plus a platinum is permitted
Prior anaphylactic or severe hypersensitivity reaction to paclitaxel or Cremophor-containing agent.
Paclitaxel therapy is appropriate for the patient and is recommended by the Investigator.
Known hypersensitivity or history of severe intolerance or toxicity to study-assigned chemotherapy. Note: History of severe hypersensitivity reactions to docetaxel (polysorbate -based formulations) for participants to be treated with MLN + docetaxel; history of hypersensitivity to carboplatin for participants to be treated with MLN + carboplatin + paclitaxel; or history of severe hypersensitivity to paclitaxel (Cremophor-based formulations) for participants to be treated with MLN + carboplatin + paclitaxel in Part B.
History of intolerance or hypersensitivity to paclitaxel and/or adverse events related to paclitaxel that resulted in paclitaxel being permanently discontinued
Patients must have received one of the regimens listed below for their platinum sensitive disease; the number of treatment cycles should not have exceeded  cycles of  regimen in the recurrent setting; the most recent dose of the regimen must have been given within  to  weeks prior to the first dose of study drug; there is a required  week washout from the last dose of chemotherapy; if greater than  weeks have passed since the last chemotherapy dose, patients may be eligible with documented approval of the Principal Investigator\r\n* Platinum (carboplatin or cisplatin) and taxane (paclitaxel or docetaxel)\r\n* Carboplatin and gemcitabine\r\n* Carboplatin and liposomal doxorubicin\r\n* Any other carboplatin doublet (including carboplatin and pralatrexate) with documented approval of the Principal Investigator
Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor) and not paclitaxel will be eligible for this study.
Prior therapy with weekly paclitaxel for recurrent disease (administration of weekly paclitaxel as part of an upfront treatment strategy is acceptable as long as the patient had not progressed while receiving weekly paclitaxel or recurred within  months of receiving weekly paclitaxel)
Patients with prior paclitaxel exposure are ineligible unless they are >  months from the conclusion of paclitaxel-based therapy
History of severe hypersensitivity reactions to docetaxel (polysorbate -based formulations) for patients to be enrolled in Arm  (MLN + docetaxel), history of hypersensitivity to carboplatin for patients to be enrolled in Arm  (MLN + paclitaxel + carboplatin), or history of severe hypersensitivity to paclitaxel (cremophor-based formulations) for patients to be enrolled in Arm 
Received prior paclitaxel therapy or had clinically documented reason why not administered
Known history of dose-limiting hypersensitivity reactions to paclitaxel/Cremophor EL
Have completed neurotoxic chemotherapy, i.e. taxanes (paclitaxel, docetaxel) and platinum (carboplatin) at least  months prior to enrollment
Patients receiving the initial course of chemotherapy including \r\n* Paclitaxel  mg/M IV over  hours on day  and \r\n* Cisplatin  mg/M IP on day   OR  \r\n* Paclitaxel  mg/m IV days ,  and  and \r\n* Carboplatin AUC  IP on day 
Planned dose-dense chemotherapy with combination carboplatin and paclitaxel given intravenously
The patients previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team
Stage II, III, or IV NSCLC for whom radiation therapy of  Gy and concurrent weekly paclitaxel/carboplatin is recommended
Known severe hypersensitivity to paclitaxel
Subject appropriate for cytoreductive surgery and treatment with IV platinum and paclitaxel
Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide
Known hypersensitivity to protein bound paclitaxel